Hope and caution: Report from the XI International Conference on AIDS

CMAJ. Canadian Medical Association Journal

Volumn 155, Issue 6, 1996, Pages 717-721

  Berger, Philip B ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; DRUG COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; REVIEW; SYMPOSIUM; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029811393     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Carpenter CCJ, Fischl MA, Hammer SM, Hirsh MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
2. Concorde Coordinating Committee. Concorde: MRC/ ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV intection. Lancet 1994;343:871-81.
3. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson CM, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med 1992,326: 437-43.